Noteworthy - Pharmaceutical Executive



Russia's Bet on Biopharma

January 21, 2014

Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector, writes William Looney.

Pharm Exec's Annual Industry Outlook 2014

January 21, 2014

For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive — muddling through is so yesterday.

Social Media: Have We Reached the Tipping Point?

January 20, 2014

FDA has released its draft guidance on the use of Interactive Promotional Media, finally providing the industry with substantial guidance on its use of digital media.

R&D in Transition

January 17, 2014

If R&D doesn't rebound, the growth prospects of R&D services providers will suffer, and even commercial CMOs will see fewer opportunities coming their way, writes Jim Miller.

Drugs, At What Cost?

January 15, 2014

As austerity, the patent cliff, and regulatory practices continue to shape the financial outlook for pharma, the key question is: What price can (or will) patients pay for the therapy?

The 7 Habits of Highly Effective Competitors

January 13, 2014

Biopharma's best companies provide valuable lessons for preparing, planning, and playing to win. Stan Bernard shows us how.

Checking the Box on Early Commercialization

January 10, 2014

Failure to improve successful launch rates will doom your company to marginalization in the fight for brand affinity — not to mention the prescriber loyalty that keeps medicines in play for the long haul.

The iPad's Future in Pharma

January 8, 2014

Three years into the Apple-led tablet era, the iPad is still being used as no more than a glorified touchscreen. Gabriel Cangiano, Ron Kane, and David Windhausen look at the key role it can play in the future of pharma.

US Pharma Challenges 2014

January 8, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing in the U.S. in 2014, writes Jill Wechsler.


Click here